Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(14):1091-1099; doi:10.1093/jnci/94.14.1091
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Bosken, C. H.
Right arrow Articles by Spitz, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bosken, C. H.
Right arrow Articles by Spitz, M. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 14, 1091-1099, July 17, 2002
© 2002 Oxford University Press

ARTICLE

An Analysis of DNA Repair as a Determinant of Survival in Patients With Non-Small-Cell Lung Cancer

Carol H. Bosken, Qingyi Wei, Christopher I. Amos, Margaret R. Spitz

Affiliation of authors: The University of Texas M. D. Anderson Cancer Center, Houston, TX.

Correspondence to: M. R. Spitz, M.D., M.P.H., Department of Epidemiology, Box 189, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030-4009 (e-mail: mspitz{at}mdanderson.org).

Background: Non-small-cell lung cancer (NSCLC) is frequently resistant to chemotherapy, and this resistance has been associated with elevated nucleotide excision repair (NER) in tumor tissue. We hypothesized that patients with NSCLC who had effective systemic (host) NER would have poorer survival than patients with suboptimal NER and that the association between NER effectiveness and survival would be most marked in patients receiving chemotherapy. Methods: 375 patients with newly diagnosed NSCLC were accrued for a case–control study between July 1995 and December 1999. NER activity was estimated as the DNA repair capacity (DRC) measured in the patient's peripheral lymphocytes by the host cell reactivation assay. Cox proportional hazards models were used to assess the association between DRC and survival. All statistical tests were two-sided. Results: For every unit (percentage) increase in DRC, the relative risk (RR) of death was 1.05 (95% confidence interval [CI] = 1.00 to 1.10; P = .05) for the 345 patients for whom weight loss information was available and 1.06 (95% CI = 1.00 to 1.12; P = .03) for the 275 patients with complete follow-up information. In 86 patients treated with chemotherapy only, the RR of death increased to 1.11 (95% CI = 1.02 to 1.21; P = .01) for every unit (percentage) increase in DRC. Of those 86 patients, patients in the top quartile of the DRC distribution were at twice the RR of death as those in the lowest quartile (RR = 2.72; 95% CI = 1.24 to 5.95; P = .01). Effective DRC was not a risk factor for death in patients who were not treated with chemotherapy. Conclusions: Our data suggest that effective host DRC may be associated with poorer survival in patients with NSCLC who are treated with chemotherapy.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Anticancer ResHome page
P. PACETTI, E. GIOVANNETTI, A. MAMBRINI, S. NANNIZZI, M. ORLANDI, R. TARTARINI, A. DEL FREO, M. DEL TACCA, R. DANESI, and M. CANTORE
Single Nucleotide Polymorphisms and Clinical Outcome in Patients with Biliary Tract Carcinoma Treated with Epirubicin, Cisplatin and Capecitabine
Anticancer Res, May 1, 2009; 29(5): 1835 - 1840.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Saviozzi, P. Ceppi, S. Novello, P. Ghio, M. Lo Iacono, P. Borasio, A. Cambieri, M. Volante, M. Papotti, R. A. Calogero, et al.
Non-Small Cell Lung Cancer Exhibits Transcript Overexpression of Genes Associated with Homologous Recombination and DNA Replication Pathways
Cancer Res., April 15, 2009; 69(8): 3390 - 3396.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Ceppi, S. Novello, A. Cambieri, M. Longo, V. Monica, M. Lo Iacono, M. Giaj-Levra, S. Saviozzi, M. Volante, M. Papotti, et al.
Polymerase {eta} mRNA Expression Predicts Survival of Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy
Clin. Cancer Res., February 1, 2009; 15(3): 1039 - 1045.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Plummer, C. Jones, M. Middleton, R. Wilson, J. Evans, A. Olsen, N. Curtin, A. Boddy, P. McHugh, D. Newell, et al.
Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors
Clin. Cancer Res., December 1, 2008; 14(23): 7917 - 7923.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
D. Breen and F. Barlesi
The place of excision repair cross complementation 1 (ERCC1) in surgically treated non-small cell lung cancer
Eur. J. Cardiothorac. Surg., May 1, 2008; 33(5): 805 - 811.
[Abstract] [Full Text] [PDF]

Home page
 MutagenesisHome page
D. J. McKenna, S. R. McKeown, and V. J. McKelvey-Martin
Potential use of the comet assay in the clinical management of cancer
Mutagenesis, May 1, 2008; 23(3): 183 - 190.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
A. Matakidou, R. el Galta, E. L. Webb, M. F. Rudd, H. Bridle, the GELCAPS Consortium, T. Eisen, and R. S. Houlston
Genetic variation in the DNA repair genes is predictive of outcome in lung cancer
Hum. Mol. Genet., October 1, 2007; 16(19): 2333 - 2340.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Cobo, D. Isla, B. Massuti, A. Montes, J. M. Sanchez, M. Provencio, N. Vinolas, L. Paz-Ares, G. Lopez-Vivanco, M. A. Munoz, et al.
Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non-Small-Cell Lung Cancer
J. Clin. Oncol., July 1, 2007; 25(19): 2747 - 2754.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. F. Giachino, P. Ghio, S. Regazzoni, G. Mandrile, S. Novello, G. Selvaggi, D. Gregori, M. DeMarchi, and G. V. Scagliotti
Prospective Assessment of XPD Lys751Gln and XRCC1 Arg399Gln Single Nucleotide Polymorphisms in Lung Cancer
Clin. Cancer Res., May 15, 2007; 13(10): 2876 - 2881.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. M. Albert, C. Cao, K. W. Kim, C. D. Willey, L. Geng, D. Xiao, H. Wang, A. Sandler, D. H. Johnson, A. D. Colevas, et al.
Inhibition of Poly(ADP-Ribose) Polymerase Enhances Cell Death and Improves Tumor Growth Delay in Irradiated Lung Cancer Models
Clin. Cancer Res., May 15, 2007; 13(10): 3033 - 3042.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Quintela-Fandino, R. Hitt, P. P. Medina, S. Gamarra, L. Manso, H. Cortes-Funes, and M. Sanchez-Cespedes
DNA-Repair Gene Polymorphisms Predict Favorable Clinical Outcome Among Patients With Advanced Squamous Cell Carcinoma of the Head and Neck Treated With Cisplatin-Based Induction Chemotherapy
J. Clin. Oncol., September 10, 2006; 24(26): 4333 - 4339.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Monzo, S. Brunet, A. Urbano-Ispizua, A. Navarro, G. Perea, J. Esteve, R. Artells, M. Granell, J. Berlanga, J. M. Ribera, et al.
Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia
Blood, June 15, 2006; 107(12): 4871 - 4879.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. Li, M. Frazier, D. B. Evans, K. R. Hess, C. H. Crane, L. Jiao, and J. L. Abbruzzese
Single Nucleotide Polymorphisms of RecQ1, RAD54L, and ATM Genes Are Associated With Reduced Survival of Pancreatic Cancer
J. Clin. Oncol., April 10, 2006; 24(11): 1720 - 1728.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R. de las Penas, M. Sanchez-Ronco, V. Alberola, M. Taron, C. Camps, R. Garcia-Carbonero, B. Massuti, C. Queralt, M. Botia, R. Garcia-Gomez, et al.
Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients
Ann. Onc., April 1, 2006; 17(4): 668 - 675.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Li, H. Liu, L. Jiao, D. Z. Chang, G. Beinart, R. A. Wolff, D. B. Evans, M. M. Hassan, and J. L. Abbruzzese
Significant effect of homologous recombination DNA repair gene polymorphisms on pancreatic cancer survival.
Cancer Res., March 15, 2006; 66(6): 3323 - 3330.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Y. Chang, R. Komaki, R. Sasaki, Z. Liao, C. W. Stevens, C. Lu, F. V. Fossella, P. K. Allen, J. D. Cox, M. R. Spitz, et al.
High Mutagen Sensitivity in Peripheral Blood Lymphocytes Predicts Poor Overall and Disease-Specific Survival in Patients with Stage III Non-Small Cell Lung Cancer Treated with Radiotherapy and Chemotherapy
Clin. Cancer Res., April 15, 2005; 11(8): 2894 - 2898.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Gu, H. Zhao, C. P. Dinney, Y. Zhu, D. Leibovici, C. E. Bermejo, H. Barton Grossman, and X. Wu
Nucleotide Excision Repair Gene Polymorphisms and Recurrence after Treatment for Superficial Bladder Cancer
Clin. Cancer Res., February 15, 2005; 11(4): 1408 - 1415.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
S. Jonsson, U. Thorsteinsdottir, D. F. Gudbjartsson, H. H. Jonsson, K. Kristjansson, S. Arnason, V. Gudnason, H. J. Isaksson, J. Hallgrimsson, J. R. Gulcher, et al.
Familial Risk of Lung Carcinoma in the Icelandic Population
JAMA, December 22, 2004; 292(24): 2977 - 2983.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
M. Taron, R. Rosell, E. Felip, P. Mendez, J. Souglakos, M. S. Ronco, C. Queralt, J. Majo, J. M. Sanchez, J. J. Sanchez, et al.
BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer
Hum. Mol. Genet., October 1, 2004; 13(20): 2443 - 2449.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
I. S. Aljada, N. Ramnath, K. Donohue, S. Harvey, J. J. Brooks, S. M. Wiseman, T. Khoury, G. Loewen, H. K. Slocum, T. M. Anderson, et al.
Upregulation of the Tissue Inhibitor of Metalloproteinase-1 Protein Is Associated With Progression of Human Non-Small-Cell Lung Cancer
J. Clin. Oncol., August 15, 2004; 22(16): 3218 - 3229.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. Isla, C. Sarries, R. Rosell, G. Alonso, M. Domine, M. Taron, G. Lopez-Vivanco, C. Camps, M. Botia, L. Nunez, et al.
Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer
Ann. Onc., August 1, 2004; 15(8): 1194 - 1203.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Gurubhagavatula, G. Liu, S. Park, W. Zhou, L. Su, J. C. Wain, T. J. Lynch, D. S. Neuberg, and D. C. Christiani
XPD and XRCC1 Genetic Polymorphisms Are Prognostic Factors in Advanced Non--Small-Cell Lung Cancer Patients Treated With Platinum Chemotherapy
J. Clin. Oncol., July 1, 2004; 22(13): 2594 - 2601.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
W. Zhou, G. Liu, D. P. Miller, S. W. Thurston, L. L. Xu, J. C. Wain, T. J. Lynch, L. Su, and D. C. Christiani
Polymorphisms in the DNA Repair Genes XRCC1 and ERCC2, Smoking, and Lung Cancer Risk
Cancer Epidemiol. Biomarkers Prev., April 1, 2003; 12(4): 359 - 365.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.